Contact Congress about S. 1818: Prescription Drug Price Relief Act of 2025

Brand-name drugs could lose special market protections if their U.S. prices are too high. Other companies could then make generic or biosimilar versions, while paying royalties to the original company.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Prescription Drug Price Relief Act of 2025 is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 1818: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects patients who use costly brand-name drugs, drug companies that sell those drugs, and companies that make generics or biosimilars. Patients, insurers, and public health programs could see lower prices if more competitors enter the market. Brand-name drug makers could lose some market protections if prices are found too high. Generic and biosimilar makers could get faster paths to enter the market under open licenses.

Why this matters: Prescription drugs can cost far more in the United States than in other wealthy countries. This bill would create a legal trigger for saying a brand-name drug price is too high. It would then open the door to faster generic or biosimilar competition. That could lower costs for patients, insurers, and public programs, but the final effect would depend on agency decisions, lawsuits, company behavior, and how fast competitors enter the market.

Key provisions in S. 1818

• HHS must review every brand-name drug at least once each calendar year to see if its price is too high.
• A drug is automatically treated as too expensive if its average U.S. manufacturer price is above the middle price in at least three of these five countries: Canada, the United Kingdom, Germany, France, and Japan.
• HHS can use a second reasonableness test when the country-price test does not catch the drug. That test looks at patient numbers, health value, development costs, public subsidies, revenue, and price hikes compared with inflation.
• Any person can ask HHS to decide whether a specific drug is priced too high. HHS must act within 90 days or publicly explain why it has not.
• For drugs found too expensive, HHS must cancel government-granted market protections and issue open, non-exclusive licenses. These licenses let any manufacturer make and sell the drug in the United States.

How Modern Action helps you take action on S. 1818

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1818

What is S. 1818?

Brand-name drugs could lose special market protections if their U.S. prices are too high. Other companies could then make generic or biosimilar versions, while paying royalties to the original company.

How do I support or oppose S. 1818?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1818?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1818 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.